Skip to main content
Caplight Logo









QLi5 Therapeutics GmbH

QLi5 Therapeutics GmbH

Private
DortmundHealthcare & Life Scienceshttps://qli5tx.com/

Last Round

Corporate Funding

Dec 18, 2025

Total Funding Raised

$17.33M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

QLi5 Therapeutics GmbH is a biotechnology company that develops a next-generation platform of non-covalent proteasome inhibitors for the treatment of cancer, inflammatory, and autoimmune disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugatesADCproteasome inhibitorsdrug discoverybiotechnologyoncologyautoimmune disorderssmall moleculetherapeutic payloadbiotechdrug developmentpreclinical researchtargeted therapybiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

QLi5 Therapeutics GmbH Comparables

Compare QLi5 Therapeutics GmbH with similar companies based on industry and business-model similarity.

QLi5 Therapeutics GmbH comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
iProtics
82%
IpiNovyx Bio
79%
Johnson & Johnson
73%

QLi5 Therapeutics GmbH Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingDec 18, 2025
Series ASep 7, 2022

QLi5 Therapeutics GmbH Investors

Notable investors and investment history

QLi5 Therapeutics GmbH investors
InvestorRounds
SV InvestmentSeries A
KTB Investment GroupSeries A
Atinum InvestmentSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 18, 2025

    $7.3M round led by Qurient Co. Ltd

QLi5 Therapeutics GmbH Filings

Explore SEC and related filing metadata, where available.

QLi5 Therapeutics GmbH filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about QLi5 Therapeutics GmbH's valuation, stock price, and market status.

Is QLi5 Therapeutics GmbH a public or private company?

QLi5 Therapeutics GmbH is a private company.

What is the current stock price of QLi5 Therapeutics GmbH?

QLi5 Therapeutics GmbH is a private company with no public stock price. No recent secondary market data is available.

How much is QLi5 Therapeutics GmbH worth (valuation)?

Valuation information for QLi5 Therapeutics GmbH is not publicly available.

Can I buy QLi5 Therapeutics GmbH stock?

QLi5 Therapeutics GmbH shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was QLi5 Therapeutics GmbH's last funding round?

QLi5 Therapeutics GmbH's most recent funding round was Corporate Funding on December 18, 2025.

Who are the main investors in QLi5 Therapeutics GmbH?

Key investors in QLi5 Therapeutics GmbH include SV Investment, KTB Investment Group, Atinum Investment.

Will QLi5 Therapeutics GmbH IPO soon?

No public IPO plans have been announced for QLi5 Therapeutics GmbH.

How can I track QLi5 Therapeutics GmbH secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor QLi5 Therapeutics GmbH's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDortmund
Employee Range1
Year Founded2019
Last FundingDec 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?